# Scandinavian Sarcoma Group

Source: https://onco.cc/companies/scandinavian-sarcoma-group/  
OnCo record `scandinavian-sarcoma-group` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Scandinavian Sarcoma Group, formed in 1979 by Nordic sarcoma physicians and scientists, writes shared treatment protocols and ran SSG XVIII, the trial that set three years of adjuvant imatinib for high-risk GIST.

## Summary

The Scandinavian Sarcoma Group (SSG) was formed in 1979 by physicians and scientists from the Scandinavian countries with a primary interest in tumours of connective tissue; its goal is to advance sarcoma care and knowledge through treatment protocols and basic and clinical research, and it is part of Lund University, with its secretariat at Barngatan 4, Lund, Sweden (ssg-org.net). ClinicalTrials.gov names it lead sponsor (OTHER class) of SSG XVIII/AIO (NCT00116935, phase 3, one against three years of adjuvant imatinib in high-risk gastrointestinal stromal tumour, run with the German AIO), the trial recorded in OnCo. It has no products of its own.

## Fields

- Kind: Company
- Last checked: 2026-09-25
- Also known as: SSG
- Tags: ctgov-sponsor; cooperative-group
- HQ: Lund
- Type: cooperative-group
- Website: https://www.ssg-org.net

## Sources

- Official website: https://www.ssg-org.net
- ClinicalTrials.gov: trials led by Scandinavian Sarcoma Group: https://clinicaltrials.gov/search?lead=Scandinavian%20Sarcoma%20Group

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [Skåne University Hospital / Lund University Cancer Centre](https://onco.cc/institutions/lund-skane/)
- trials: [SSGXVIII/AIO (adjuvant imatinib in GIST)](https://onco.cc/trials/ssgxviii/)

---
JSON: https://onco.cc/api/v1/entities/scandinavian-sarcoma-group.json